## **ICMJE DISCLOSURE FORM**

Date:	8/2/2021
Your Name:	Jeroen Hermanides
Manuscript Title:	Bijspuitschema in de ban
Manuscript Number (if known):	D8297R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
present manuscript (e.g funding, provis of study mater medical writing article processi charges, etc.) No time limit fo this item.  2 Grants or contracts from any entity (if r	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Time frame: past 36 month  □ None  ZonMW GGG grant; "Improvement of postoperative glucose control to lower surgical	Click the tab key to add additional rows.  Granted 2023, payments to Amsterdam UMC
		site infections 30 days after surgery in patients with diabetes mellitus type 2: a basal-bolus insulin regimen versus a sliding-scale regimen; The GUIDE trial"  ZonWM GGG grant "SGLT2 inhibition for the prevention of acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass: a step towards sex-based medicine"	Granted 2021, payments to Amsterdam UMC

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
ъ.	Royalties or licenses	Royalties as editor of A&I teaching magazine	Prelum uitgevers
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Payment for teaching activities Nederlandse Vereniging voor Anesthesiologie Payment for teaching activities CEAA cursus, stichting CEAA	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board,	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	Penningmeester onbezoldigd Stichting Claudia Potter		
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.				